New Search

Advanced search
Export article
Open Access

Anti-GnRH Neutralizing Antibodies Produce Testosterone Ablation and Tumor Shrinkage in Prostate Cancer Models

Jesús A. Junco, Franklin Fuentes, Lesvia Calzada, Eddy Bover, Eulogio Pimentel, Yovisleidis López, Roberto Basulto, Hilda Garay, Osvaldo Reyes, Angel Cid-Arregui, Maria D. Castro, Rafael Martínez, Niurka Arteaga, Ana Campal, Ayni Rodríguez, Andrés Serradelo, Eduardo Hernández, Mirialis Arias, Raúl González, Matilde López, Gisell Bebert, Gerardo Guillén
Journal of Cancer Science and Clinical Therapeutics , Volume 4, pp 333-348; doi:10.26502/jcsct.5079076

Abstract: Background: Vaccines based on modified GnRH peptide variants can be an alternative treatment for advanced prostate cancer. However, the efficacy of the GnRH-based vaccine variants has been limited by their insufficient immunogenicity. Methods: The current vaccine based on the modified peptide GnRHm1-TT peptide has been formulated in the different oil adjuvants; Montanide ISA 51 and Montanide ISA 51VG. Results: Experiments carried out in healthy animal models demonstrated to produce significant anti-GnRH antibody levels (p
Keywords: Antibody / vaccine / Efficacy / model / tumor / Prostate / Dunning R3327 / Neutralize / ISA 51VG

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "Journal of Cancer Science and Clinical Therapeutics" .
Back to Top Top